Dr Keren Middelkoop (TB Division Lead) is a clinical researcher at the DTHC/F. She has implemented a range of observational and epidemiological studies to explore the interaction of HIV and TB epidemics at a population level, and the impact of ART on TB in communities with high burdens of both diseases, including TB and HIV prevalence cross-sectional surveys and TB infection and transmission studies utilizing both tuberculin skin testing and a >10 year molecular epidemiological community cohort.
She is local PI on a phase 3 clinical trial, assessing vitamin D supplementation for prevention of TB infection. Her epidemiological work explores methods for detecting airborne Mtb in congregate settings with a view to operationalizing more targeted TB active case finding. She serves as local PI for the HPTN 083 study that recently reported the benefit of Cabotegravir for pre-exposure prophylaxis.